MAGE-A4 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene"

Trial Profile

MAGE-A4 peptide vaccine study after "Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene"

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2014

At a glance

  • Drugs CHP-MAGE-A4 (Primary) ; Montanide ISA-51
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Nov 2014 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 09 May 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
    • 10 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top